

Harvard Apparatus Regenerative Technology, Inc.  
Form 8-K  
October 17, 2014

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): October 17, 2014

**HARVARD APPARATUS REGENERATIVE TECHNOLOGY, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**                      **001-35853**                      **45-5210462**  
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

**84 October Hill Road, Holliston, MA 01746**

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: **(774) 233-7300**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events.**

On October 17, 2014, Harvard Apparatus Regenerative Technology, Inc., or the Company, issued a press release announcing that it has recently been informed by the principal investigator in the Russian regenerated trachea transplant studies in which it is taking part that one of the patients in that study has recently passed away. The Company has not been informed of the cause of death. The patient survived more than two years from the initial regenerated trachea transplant surgery that took place in 2012. Prior to that surgery, the patient had suffered several instances of life threatening respiratory failure and infections. The patient was indicated for the initial transplant surgery because there was both a progression of the respiratory failure and traditional tracheal surgery was impossible. The press release is furnished as Exhibit 99.1 and incorporated herein by reference.

The information in Item 8.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the United States Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the United States Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

<b>Exhibit Number</b>	<b>Title</b>
---------------------------	--------------

99.1	Press release of Harvard Apparatus Regenerative Technology, Inc., issued on October 17, 2014.
------	---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Harvard Apparatus Regenerative  
Technology, INC.**  
(Registrant)

**October 17, 2014** /s/ **Thomas McNaughton**  
(Date) Thomas McNaughton  
*Chief Financial Officer*

**INDEX TO EXHIBITS**

**Exhibit**

**Description of Exhibit**

**Number**

99.1 Press Release issued by Harvard Apparatus Regenerative Technology, Inc. on October 17, 2014.